Search

Your search keyword '"Lonardi, S"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Lonardi, S" Remove constraint Author: "Lonardi, S" Topic medicine Remove constraint Topic: medicine
66 results on '"Lonardi, S"'

Search Results

1. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

3. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

4. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma

5. QoL is a cool tool

6. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

7. Anaplastic lymphoma kinase in human cancer

8. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial

9. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

10. The Italian Rare Pancreatic Exocrine Cancer Initiative

11. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib

12. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience

13. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

14. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

15. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

16. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

17. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

18. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

19. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

20. Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

21. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

22. Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

23. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

24. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

25. Life After Death: The Devil's Details

26. Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?

27. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

28. From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy

29. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM)

30. Central Nervous System as Possible Site of Relapse in ERBB2 -Positive Metastatic Colorectal Cancer: Long-term Results of Treatment with Trastuzumab and Lapatinib

31. Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib

32. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

33. Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a

34. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials

35. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)–cT3 rectal cancer

36. Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization

37. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

38. Gastric cancer: Translating novels concepts into clinical practice

39. Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort

40. Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

41. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

42. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

43. TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

44. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

45. Bone metastases in biliary cancers: A multicenter retrospective survey

46. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3ß inhibition

47. Erratum to 'Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life' [Eur J Cancer 69 (2016) 110-118]

48. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

49. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

50. Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight

Catalog

Books, media, physical & digital resources